Chemical formula: C₁₇H₂₅N₃O₂S Molecular mass: 335.464 g/mol PubChem compound: 4440
Naratriptan interacts in the following cases:
Naratriptan should be used with caution in patients with renal impairment. The maximum dose in any 24 hour treatment period is 2.5 mg.
Naratriptan should be used with caution in patients with hepatic impairment. The maximum dose in any 24 hour treatment period is 2.5 mg.
Oral contraceptives decrease the total clearance of naratriptan by 30%, and smoking increases total clearance by 30%. But no dosing adjustments are required.
Serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) has been reported following concomitant treatment with triptans and SSRIs/SNRIs.
Evaluation of experimental animal studies does not indicate any direct teratogenic effects or harmful effects on peri- and postnatal development. However, delays in foetal ossification and possible effects on embryo viability have been observed in the rabbit.
Post-marketing data from prospective pregnancy registries have documented the pregnancy outcomes in less than 60 women exposed to naratriptan. Due to a small sample size no definitive conclusion can be drawn regarding the risk of birth defects following exposure to naratriptan.
Because animal reproduction studies are not always predictive of human response, administration of naratriptan should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus.
Naratriptan and/or drug related metabolites are secreted into the milk of lactating rats. Transient effects in the pre and post-natal development of neonatal rats were observed only at maternal exposures sufficiently in excess of maximum human exposure. No studies have been conducted to determine the level of transference of naratriptan into breast milk of nursing women. It is recommended that infant exposure be minimised by avoiding breast-feeding for 24 hours after treatment.
Drowsiness may occur as a result of migraine or its treatment with naratriptan. Caution is recommended when skilled tasks are to be performed (e.g. driving or operating machinery).
At therapeutic doses of naratriptan the incidence of side effects reported in clinical trials was similar to placebo. Some of the symptoms may be part of the migraine attack.
Undesirable effects are ranked under headings of frequency using the following convention: Very common (≥1/10), common (≥1/100 and <1/10), uncommon (≥1/1,000 and <1/100), rare (≥1/10,000 and <1/1,000) and very rare (<1/10,000).
Rare: Hypersensitivity reactions ranging from cutaneous hypersensitivity to rare cases of anaphylaxis.
Common: Tingling. This is usually of short duration, may be severe and may affect any part of the body including the chest or throat. Dizziness and somnolence.
Uncommon: Visual disturbance.
Uncommon: Bradycardia, tachycardia, palpitations.
Very Rare: Coronary artery vasospasm, transient ischaemic ECG changes, angina and myocardial infarction.
Very rare: Peripheral vascular ischaemia.
Common: Nausea and vomiting.
Rare: Ischaemic colitis.
Skin and subcutaneous tissue disorders
Rare: Rash, Urticaria, Pruritis, facial oedema
The following symptoms are usually of short duration, may be severe and may affect any part of the body including the chest or throat:
Common: Sensations of heat, malaise/fatigue.
Uncommon: Pain, sensations of heaviness, pressure or tightness.
Uncommon: Increase in blood pressure of approximately 5mmHg (systolic) and 3 mmHg (diastolic) in a period of upto 12 hours after administration.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
